RE:RE:RE:RE:I'm concerned ."Why does market think differently."
The market will want to see certain proof points.
What are the diagnostic test results to be released in Q3 and who will license the test and for what? How compelling are the results?
Will PGX be successfully scaled from the lab to the first commercial product and to the decision point for mass industrialization. After due diligence who will license it or partner and one what terms? Having an expert company kick the tires and sign a deal is important validation.
What are the safety/tolerability, and preliminary efficacy results for the avenanthramide pill from the Phase I/IIa clinical trial. Does it look like a viable product.
What is the regulatory path forward for the NMOSD project? How costly? Does AEZS have a compelling preclinical case?
We are before critical proof points or proofs of principle as mentioned above. Nailing down these key proof points and a path to a sustainable company should help secure analyst and market support. We are very early before the key proofs.